Biomarker and Target Identification in GEP-NET: From in Silico Prediction to Validation on Patient Tissues

#1483

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors. Somatostatin agonist treatment has a key role in the management of GEP-NET. However, the prognosis of these tumors varies between individuals. There is, therefore, a need to identify novel prognostic and predictive biomarkers of therapeutic efficacy, as well as to propose novel therapeutic strategies.

Aim(s): To optimize this approach, we adopted a strategy that uses a curated biological knowledge source coupled with a proprietary data mining methodology (iFit) followed by wet lab experiments. In this poster, we highlight some of the results of the experimental validation.

Materials and methods: We selected 10 miRs and 42 mRNAs coding for G protein coupled receptors (GPCRs) that were identified with iFiT, for evaluation in tumor functioning or not from 40 metastatic or not patients (20 pancreatic NET and 20 ileal NET). The nanostring® platform was used for miRNAs and mRNAs analysis and immunohistochemistry was carried out for 11 GPCRs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Tourlet S, Gentien D, Bauchet A, Nicolas A, Blachon J,

Keywords: GPCR, miR,